MedTrace Logo

Belimumab In Early Systemic Lupus Erythematosus

NCT04956484 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2022-07-08

No results posted yet for this study

Summary

To investigate the efficacy of belimumab in early SLE patients (disease duration less than 6 months).

Conditions

  • Lupus Erythematosus, Systemic

Interventions

BIOLOGICAL

Belimumab

Belimumab 10 mg/kg

DRUG

Standard of care

Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2022-04-08
Completion
2022-04-08
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04956484 on ClinicalTrials.gov